Liang Bing, He Xinwei, Shang Donghao, Tian Ye, Liu Zongwen
Department of Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Department of Infection, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Oncol Lett. 2018 Feb;15(2):1483-1486. doi: 10.3892/ol.2017.7504. Epub 2017 Nov 29.
We studied the expression level of FOXJ1 in bladder epithelial carcinoma and its relation to clinical features and tumor recurrence. From January 2014 to June 2015, 66 patients with bladder epithelial carcinoma were enrolled in this study and their tumor and para-carcinoma tissue samples were collected. FOXJ1 positive expression rate was evaluated using immunohistochemical staining, and FOXJ1 mRNA expression level was measured by RT-PCR. RT-PCR and immunohistochemistry results showed that FOXJ1 expression level in tumor samples was significantly lower than that in para-carcinoma tissue samples. The median survival time in patients with positive expression of FOXJ1 was significantly longer than that of patients with negative expression of FOXJ1. We also showed that FOXJ1 expression level was negatively correlated with neoplasm staging and tumor recurrence rate. We concluded that FOXJ1 was expressed in low quantities in bladder epithelial carcinoma, which was closely correlated with the biological characteristics of the tumor. FOXJ1 expression presents a promising application prospect for further exploration of the specific biological mechanism of FOXJ1 in regulating the occurrence and development of bladder epithelial carcinoma. FOXJ1 may be used as a new marker for early diagnosis and prediction of recurrence.
我们研究了FOXJ1在膀胱上皮癌中的表达水平及其与临床特征和肿瘤复发的关系。2014年1月至2015年6月,本研究纳入66例膀胱上皮癌患者,并收集其肿瘤及癌旁组织样本。采用免疫组织化学染色评估FOXJ1阳性表达率,通过RT-PCR检测FOXJ1 mRNA表达水平。RT-PCR和免疫组织化学结果显示,肿瘤样本中FOXJ1表达水平显著低于癌旁组织样本。FOXJ1阳性表达患者的中位生存时间显著长于FOXJ1阴性表达患者。我们还发现FOXJ1表达水平与肿瘤分期和肿瘤复发率呈负相关。我们得出结论,FOXJ1在膀胱上皮癌中低表达,这与肿瘤的生物学特性密切相关。FOXJ1表达为进一步探索FOXJ1调控膀胱上皮癌发生发展的具体生物学机制提供了有前景的应用前景。FOXJ1可作为早期诊断和预测复发的新标志物。